GlassScriptPhysician profile
Rajesh K Sadasivuni
NPI 1780998658
$3,718.97
in general payments reported to CMS, 2019-2025
30 companies · $1,151 in 2025
The $1,151 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $29.64 · 2022: $388 · 2023: $839 · 2024: $1,312 · 2025: $1,151.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,301.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,301.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $420.63 | 2021-2025 | Zilbrysq, Briviact, Fintepla |
| Genentech USA, INC. | $400.79 | 2023-2025 | Ocrevus, Enspryng, Ocrevus Zunovo |
| Argenx US, INC. | $372.27 | 2023-2025 | Vyvgart, Vyvgart Hytrulo |
| Novartis Pharmaceuticals Corporation | $351.64 | 2022-2025 | |
| Lundbeck LLC | $345.48 | 2022-2025 | Vyepti |
| Genentech, INC. | $344.86 | 2022-2025 | Ocrevus |
| Emd Serono, INC. | $246.01 | 2024-2025 | Mavenclad |
| Biogen, INC. | $211.73 | 2022-2025 | Vumerity, Tysabri, Avonex |
| Tg Therapeutics, INC. | $146.92 | 2024 | |
| Janssen Biotech, INC. | $123.84 | 2025 | |
| Abbvie INC. | $83.51 | 2022-2023 | Qulipta |
| Jazz Pharmaceuticals INC. | $81.11 | 2024-2025 | |
| Mallinckrodt Hospital Products INC. | $70.16 | 2024-2025 | Acthar |
| Medtronic, INC. | $65.73 | 2024-2025 | Linq II, Intellis Adaptivestim |
| Vanda Pharmaceuticals INC. | $60.02 | 2025 | Ponvory |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $56.70 | 2024 | |
| Sk Life Science, INC. | $42.15 | 2023 | Xcopri |
| Sumitomo Pharma America, INC. | $30.11 | 2023 | Aptiom |
| Neurelis, INC. | $30.06 | 2025 | Valtoco |
| Janssen Pharmaceuticals, INC | $29.16 | 2022 | |
| Pfizer INC. | $27.26 | 2025 | |
| Acadia Pharmaceuticals INC | $27.23 | 2023-2024 | Daybue, Nuplazid |
| Merz Pharmaceuticals, LLC | $23.38 | 2025 | Inbrija, Xeomin |
| Ns Pharma, INC. | $22.65 | 2025 | Viltepso |
| Ani Pharmaceuticals, INC. | $21.36 | 2025 | Purified Cortrophin Gel |
| Livanova USA, INC. | $20.74 | 2025 | Vns Therapy Sentiva Model 1000 Generator |
| Xeris Pharmaceuticals, INC. | $19.19 | 2025 | Keveyis |
| Amneal Pharmaceuticals LLC | $18.25 | 2025 | Crexont |
| Grifols USA, LLC | $14.08 | 2024 | Gamunex-C |
| Celgene Corporation | $11.95 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajesh Sadasivuni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.